A Cost-Per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
June 2026
in “
Journal of health economics and outcomes research
”
Studysummary This study found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg for treating severe alopecia areata at Weeks 24 and 52, potentially influencing reimbursement decisions.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on jheor.org →